Fact based stock research
Realcan Pharmaceutical (SZSE:002589)
Realcan Pharmaceutical stock research in summary
realcan.cn
Realcan Pharmaceutical shares have a market-typical stock price level. They are safely financed and are good value, but show below average growth. We recommend evaluating whether the future of the company Realcan Pharmaceutical is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.
Latest Obermatt Ranks
Country |
China |
Industry |
Health Care Distributors |
Index |
|
Size class |
X-Large |
December 6, 2019. Stock data may be delayed. Login to get the most recent research.
Google: Realcan Pharmaceutical
Research History: Realcan Pharmaceutical
Last update of Combined Rank: 6-Dec-2019. Financial reporting date used for calculating ranks: 30-Sep-2019. Stock research history is based on the Obermatt Method. The higher the rank, the better Realcan Pharmaceutical is in the corresponding investment strategy.
Value Metrics in Detail
Last update of Value Rank: 6-Dec-2019. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Realcan Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.
Growth Metrics in Detail
Last update of Growth Rank: 30-Sep-2019. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Realcan Pharmaceutical.
Safety Metrics in Detail
Last update of Safety Rank: 29-Nov-2019. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Realcan Pharmaceutical and the more cash is available to service its debt.
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Realcan Pharmaceutical from December 6, 2019.